Atlas Trials

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Clinical trial NCT06385483 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06385483
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Multiple Myeloma
Start date
2018-02-28
Primary completion
2022-12-06
Enrollment
19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.